Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.58 |
| ▸ | MPO | P05164 | 11/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324836 | 0.83 | GPR84 (0.58) | GPR84HTR2AHTR1ASLC6A4 | |
| Ethoxycarbonyl Group SCHEMBL27451341 | 0.81 | MPO (0.47) | GPR84MPOHTR2ATRPM8HTR2C | |
| SCHEMBL38663621 | 0.78 | GPR84 (0.62) | GPR84HTR2ATRPM8SLC6A4 | |
| SCHEMBL20584073 | 0.78 | GPR84 (0.62) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL20846130 | 0.77 | GPR84 (0.49) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL25762360 | 0.77 | GPR84 (0.60) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL15623086 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL14631802 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL8259062 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL1372357 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-29 | — | — | US | disclosed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. | 2023-02-09 | — | — | US | disclosed |
| CN-115484947-A | Selective Androgen Receptor Degrader (SARD) ligands and methods of use thereof | 田纳西大学研究基金会 | 2022-12-16 | — | — | CN | disclosed |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210253525-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-08-19 | — | — | US | disclosed |
| CN-113164435-A | Selective Androgen Receptor Degrader (SARD) ligands and methods of use thereof | 田纳西大学研究基金会 | 2021-07-23 | — | — | CN | disclosed |
| US-20210196678-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-06-03 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1683800-A1 | PROCESS FOR PRODUCING THIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | GPR84 1536/4885MPO 412/4885HTR2A 2816/4885 |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | GPR84 852/4885MPO 4863/4885HTR2A 214/4885 |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | AR, BRCA1, FSHR | GPR84 849/4885MPO 4868/4885HTR2A 400/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | GPR84 2471/4885MPO 23/4885HTR2A 3838/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | GPR84 2766/4885MPO 110/4885HTR2A 2707/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | GPR84 2766/4885MPO 110/4885HTR2A 2707/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | GPR84 849/4885MPO 4868/4885HTR2A 400/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | GPR84 852/4885MPO 4863/4885HTR2A 214/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | GPR84 2766/4885MPO 110/4885HTR2A 2707/4885 |
| US-20210253525-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | GPR84 852/4885MPO 4863/4885HTR2A 214/4885 |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | GPR84 852/4885MPO 4863/4885HTR2A 214/4885 |
| US-20210196678-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, FSHR | GPR84 840/4885MPO 4871/4885HTR2A 337/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | GPR84 852/4885MPO 4863/4885HTR2A 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.